Document Detail


Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study.
MedLine Citation:
PMID:  16029995     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This multicenter, three-armed, open-labeled study investigated patient compliance of patients receiving irbesartan, angiotensin-converting enzyme (ACE) inhibitors or calcium-channel blockers (CCB) for essential hypertension for a 6-month period. Patients were either newly diagnosed or switched from existing antihypertensive medication due to lack of efficacy or side-effects. METHODS: Patients were started monotherapy with irbesartan (n = 377), ACE inhibitors (n = 298) or CCB (n = 308) and were reevaluated on 1st, 3rd, and 6th months of the treatment. The primary endpoint was patient compliance, assessed by proportion of patients who had taken their study medication every day. Efficacy was recorded as mean reductions in blood pressure and the proportion of patients whose blood pressure normalized. Tolerability was assessed by reported adverse events. RESULTS: Significantly more patients receiving irbesartan had complied with study medication after 3 and 6 months of treatment than ACE inhibitors or CCB. Significantly fewer patients receiving irbesartan needed to change their antihypertensive medication. All three study treatments exhibited similar efficacy profiles, but irbesartan had significantly less adverse events. CONCLUSIONS: This study demonstrated that patient compliance to irbesartan was significantly superior to other study treatments. Irbesartan is therefore a suitable first-line therapy for essential hypertension in everyday clinical practice.
Authors:
Nevres Koylan; Esmeray Acarturk; Aykan Canberk; Nail Caglar; Sali Caglar; Serap Erdine; Sema Guneri; Baris Ilerigelen; Giray Kabakci; Remzi Onder; Olcay Sagkan; Kemalettin Buyukozturk;
Related Documents :
464345 - Hypertension detection and compliance: permanent site hypertensive evaluation--a new me...
1691415 - Enalapril: benefit-to-risk ratio in hypertensive patients.
15269705 - Moxonidine in the treatment of overweight and obese patients with the metabolic syndrom...
17377975 - Intensive treatment of hypertension decreases the risk of hyperperfusion and intracereb...
464345 - Hypertension detection and compliance: permanent site hypertensive evaluation--a new me...
22542995 - Differences in faecal bacteria populations and faecal bacteria metabolism in healthy ad...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Blood pressure. Supplement     Volume:  14 Suppl 1     ISSN:  0803-8023     ISO Abbreviation:  Blood Press Suppl     Publication Date:  2005  
Date Detail:
Created Date:  2005-07-20     Completed Date:  2009-01-28     Revised Date:  2010-05-18    
Medline Journal Info:
Nlm Unique ID:  9300787     Medline TA:  Blood Press Suppl     Country:  Norway    
Other Details:
Languages:  eng     Pagination:  23-31     Citation Subset:  IM    
Affiliation:
Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. nevres@koylan.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Biphenyl Compounds / adverse effects,  therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / therapeutic use*
Constipation / chemically induced
Female
Headache / chemically induced
Heartburn / chemically induced
Humans
Hypertension / diagnosis,  drug therapy*
Male
Middle Aged
Multivariate Analysis
Nausea / chemically induced
Patient Compliance*
Tetrazoles / adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Xerostomia / chemically induced
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Calcium Channel Blockers; 0/Tetrazoles; 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in pa...
Next Document:  Nifedipine OROS in Chinese patients with hypertension - results of a post-marketing surveillance stu...